|Awarded On||August 18, 2021|
|Title||Targeted Therapeutic Drug Discovery & Development Program|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Kevin Dalby|
|Cancer Sites||All Sites|
*Pending contract negotiation
8.2.2. Layperson’s Summary Drug discovery research is a moving target, continually adapting to the opportunities afforded by new technologies. While cancer researchers have identified many clinically significant cancer-related targets, the critical challenge in advancing new molecules from ‘discovery’ to pre-clinical testing is the lack of ac-cess to the specialized and cutting-edge resources instrumented by multi-disciplinary experiences that are necessary to support the early phase of drug development effort. The GCC for Innovative Drug Discovery and Development (GCC-IDDD) goal has been to provide Texas’ re-searchers with access to cutting-edge technologies and expertise to enable the ...